Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RayzeBio, Inc. - Common Stock (NQ:RYZB)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about RayzeBio, Inc. - Common Stock

News headline image
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments ↗
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer... 
Via Benzinga
News headline image
The Best-Performing U.S. IPOs Of 2023 ↗
In 2023, there were 154 IPOs on the U.S. stock market. Here is a look at some of the best initial public offerings from last year. 
Via Talk Markets
News headline image
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
News headline image
Cramer Says This 'Inexpensive' Stock Is 'Doing Some Great Things With Aerospace' ↗
Jim Cramer said WK Kellogg Co (NYSE: KLG) doesn’t have a "lot of growth, and it doesn’t have a lot of yield." He prefers Kellanova (NYSE: K) 
Via Benzinga
News headline image
Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio ↗
 
Via Benzinga
News headline image
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review ↗
The major indexes boast big annual gains with the Dow at record highs. 
Via Investor's Business Daily
Topics Stocks
News headline image
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
News headline image
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned ↗
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole... 
Via Benzinga
News headline image
Investor Sentiment Improves; Dow Jumps Over 150 Points ↗
The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The... 
Via Benzinga
Topics Stocks
News headline image
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Stocks Extend Gains As Oil Prices Rise ↗
The short sprint to the end of 2023 is off to a good start, with the Dow Jones Industrial Average, S&P 500 Index, and Nasdaq Composite all sporting solid gains this afternoon. 
Via Talk Markets
Topics Stocks
News headline image
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100% ↗
Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower. 
Via Investor's Business Daily
News headline image
Why Is RayzeBio (RYZB) Stock Up 100% Today? ↗
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024. 
Via InvestorPlace
News headline image
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals ↗
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of < 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023 ↗
 
Via Benzinga
News headline image
RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan ↗
JP Morgan has initiated coverage on RayzeBio Inc (NASDAQ: RYZB), representing a pure-play opportunity in the radiopharmaceutical space. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023 ↗
 
Via Benzinga
News headline image
Specialty Asian Grocer Maison Solutions Opens For Trading ↗
Following a couple of high-profile trading debuts, the IPO market slowed down again. There was only one public offering of note this week, with California-based specialty Asian grocer Maison Solutions... 
Via Talk Markets
Topics Initial Public Offering
News headline image
SoftBank-Owned Arm Jumps 20% In Market Debut ↗
British chip designer Arm made its public debut on Thursday, with the shares jumping 10% right as the stock opened for trading. Arm's was the most high-profile Nasdaq IPO in the last few years, with... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.